We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Solventum Corporation (SOLV) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Solventum (SOLV - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Solventum is one of 974 companies in the Medical group. The Medical group currently sits at #7 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Solventum is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for SOLV's full-year earnings has moved 6.1% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, SOLV has gained about 10.8% so far this year. In comparison, Medical companies have returned an average of -2.7%. As we can see, Solventum is performing better than its sector in the calendar year.
ANIXA BIOSCIENCES INC (ANIX - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 51.7%.
The consensus estimate for ANIXA BIOSCIENCES INC's current year EPS has increased 7.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Solventum is a member of the Medical Services industry, which includes 58 individual companies and currently sits at #99 in the Zacks Industry Rank. Stocks in this group have lost about 2.6% so far this year, so SOLV is performing better this group in terms of year-to-date returns.
On the other hand, ANIXA BIOSCIENCES INC belongs to the Medical - Biomedical and Genetics industry. This 485-stock industry is currently ranked #105. The industry has moved +2.8% year to date.
Investors with an interest in Medical stocks should continue to track Solventum and ANIXA BIOSCIENCES INC. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Solventum Corporation (SOLV) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Solventum (SOLV - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Solventum is one of 974 companies in the Medical group. The Medical group currently sits at #7 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Solventum is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for SOLV's full-year earnings has moved 6.1% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, SOLV has gained about 10.8% so far this year. In comparison, Medical companies have returned an average of -2.7%. As we can see, Solventum is performing better than its sector in the calendar year.
ANIXA BIOSCIENCES INC (ANIX - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 51.7%.
The consensus estimate for ANIXA BIOSCIENCES INC's current year EPS has increased 7.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Solventum is a member of the Medical Services industry, which includes 58 individual companies and currently sits at #99 in the Zacks Industry Rank. Stocks in this group have lost about 2.6% so far this year, so SOLV is performing better this group in terms of year-to-date returns.
On the other hand, ANIXA BIOSCIENCES INC belongs to the Medical - Biomedical and Genetics industry. This 485-stock industry is currently ranked #105. The industry has moved +2.8% year to date.
Investors with an interest in Medical stocks should continue to track Solventum and ANIXA BIOSCIENCES INC. These stocks will be looking to continue their solid performance.